Ryan Specialty 10-Q: Q3 Organic Growth Slows to 4.0%, Net Income Up 41% to $88.0M
RYAN sits 44% above its 52-week low of $29.28.
Summary
Ryan Specialty's Q3 10-Q confirms the organic growth slowdown to 4.0% disclosed yesterday, alongside 41% higher net income of $88.0M, $450.3M of nine-month buybacks and a revolver drawn up to $422.8M.
Key Events · Earnings and Guidance · RYAN
-
Organic Growth Decelerates Sharply
Q3 organic revenue growth fell to 4.0% from 15.0% a year ago, the sharpest slowdown in recent quarters, as property rates declined and retailers placed more coverage directly. Total revenue still rose 4.7% to $790.0M.
-
Net Income Up 41% to $88.0M
Diluted EPS rose to $0.29 from $0.20 and adjusted diluted EPS to $0.51 from $0.47. Adjusted EBITDAC was $244.4M, a 30.9% margin versus 31.2% a year ago.
-
Restructuring Costs Weigh on Margins
The Empower program carries $160.0M of expected total cost, with $62.0M incurred in the first nine months and roughly $80.0M of annual savings targeted for 2029. The compensation and benefits ratio rose to 61.3% from 58.4%.
-
Buybacks and Higher Revolver Draw
The company repurchased 12,658,436 Class A shares for $450.3M in the nine months and 1,310,583 more for $50.0M through October 29, 2026, leaving $150.0M available. Revolving credit borrowings rose to $422.8M from $73.2M at year-end.
Analysis · RYAN · Finance
The headline broke yesterday: organic revenue growth collapsed to 4.0% from 15.0% a year ago, the sharpest deceleration in recent memory, even though total revenue still rose 4.7% to $790.0M. What this 10-Q adds is the full picture behind that number. Net income jumped 41% to $88.0M and diluted EPS rose to $0.29 from $0.20, helped by a $10.7M favorable swing in contingent consideration and lower acquisition costs, while adjusted EBITDAC margin slipped to 30.9% from 31.2% as the Empower restructuring ($62.0M incurred so far against a $160.0M plan) pushed the compensation ratio up to 61.3%. The company also bought back 12.7M shares for $450.3M in the first nine months and another $50.0M through October 29, leaving $150.0M on the authorization, and drew its revolver up to $422.8M from $73.2M at year-end. The decelerating organic growth is the number that matters for the thesis; the buyback and cost program are offsets, not fixes.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RYAN was trading at $42.30 on NYSE in the Finance sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $29.28 to $58.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.